Drug Discovery In Neuroscience: Kevin Gorman , Ceo, Neurocrine Biosciences

Drug Discovery in Neuroscience: Kevin Gorman (Ph.D. ’87, ’91), CEO, Neurocrine Biosciences

Neurocrine Biosciences, Inc NBIX CEO Kevin Gorman on Q2 2020 Results

Daily Earnings Calls

Revolutionizing Drug Discovery: The Power of Generative Biology and AI

Sponsor Perspective: Neurocrine Biosciences | The New Role of Telehealth

The Hill Events

News Update: Neurocrine Biosciences Said Potential Treatment For Depressive Disorder Was Ineffective

Nasdaq San Diego: Neurocrine

Neurocrine Biosciences - 2022 State Conference Sponsor

NAMI Mississippi

Neurocrine Biosciences | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks

Biotech Stocks 1202

Meeting the Challenge: Neuroscience Drug Discovery with the Warren Center

Vanderbilt University

Neurocrine Update

HDYO

How the PHERAstar FSX and its software support drug discovery in neuroscience

Neurocrine Biosciences | Wikipedia audio article

The Academic Perspective of the Challenges of Drug Discovery

British Neuroscience Association

Session I: Meeting the Challenges in MS and Neuroscience Drug Development

The Changing Neuroscience Drug Discovery Landscape in the UK

Medicines Discovery Catapult

Advances in CNS Drug Discovery: Focus on Neurodegenerative Diseases

WuXi Discovery Services

Neurotranslation to address the attrition problem in neuroscience drug discovery, Dr. Ismail Kola

The Brain Forum

Neurocrine INGREZZA Outstanding Product, Therapeutics Award | PANTHEON 2017 PRESENTING DiNA™ AWARDS

California Life Sciences (CLS)

Student experience - Celina Worraker - Drug Discovery and Development at Leeds

Faculty of Biological Sciences

Research Blitz: Neurocrine, Prilenia, uniQure, Wave, Novartis, Sage, and HDClarity

Huntington Study Group